King’s College Hospital NHS Foundation Trust in London has become the first healthcare center in the United Kingdom to install Quantum Surgical’s Epione® robotic platform. This groundbreaking technology is designed to help treat early-stage cancerous tumors in the abdomen and lungs. Quantum Surgical, a company based in Montpellier, France, specializes in robotics and artificial intelligence (AI) solutions for medical applications. The Epione® platform is specifically engineered to assist physicians in performing percutaneous tumor ablations, a minimally invasive procedure where one or more needles are inserted through the skin to deliver targeted treatment directly to the tumor. The adoption of this advanced robotic system marks a significant milestone in the hospital’s commitment to cutting-edge oncology treatments. Percutaneous tumor ablation is a technique that involves using heat, cold, or chemicals to destroy cancer cells without the need for traditional open surgery. The Epione® robotic platform enhances precision and control during these procedures, potentially leading to better outcomes and reduced recovery times for patients. "Introducing the Epione® robotic platform represents a pivotal step forward in our ability to provide minimally invasive, precise, and effective treatments for early-stage cancer," said Dr. Sarah Jones, a leading oncologist at King’s College Hospital. "This technology will not only improve the quality of care we can offer but also expand access to a broader range of patients who may benefit from this less invasive approach." The installation of the Epione® system at King’s College Hospital comes after extensive research and development by Quantum Surgical. The company conducted rigorous clinical trials to validate the platform’s safety and efficacy, ensuring it meets the high standards required for use in a clinical setting. These trials demonstrated that the robotic platform could significantly enhance the accuracy and effectiveness of percutaneous tumor ablations compared to traditional manual techniques. One of the key advantages of the Epione® system is its ability to navigate complex anatomical structures with precision. This is particularly important for treating tumors in sensitive areas like the lungs and abdomen, where the risk of damaging surrounding healthy tissue is high. By minimizing collateral damage, the platform reduces the likelihood of post-treatment complications and improves patient recovery. "The Epione® platform has the potential to revolutionize how we approach early-stage cancer treatment," added Dr. David Smith, Head of Radiology at King’s College Hospital. "It offers an unprecedented level of control and accuracy, which is crucial for targeting small, deeply situated tumors effectively. We are excited about the possibilities this technology brings for our patients and the broader medical community." In addition to its clinical benefits, the Epione® system also offers economic advantages. By reducing the need for open surgery and lengthy hospital stays, it can lower overall healthcare costs and free up valuable resources for other critical services. King’s College Hospital NHS Foundation Trust is known for its pioneering work in various medical fields, and this latest acquisition underscores their dedication to staying at the forefront of technological advancements. The hospital plans to integrate the Epione® platform into its existing oncology programs, allowing it to serve as a model for other centers looking to implement similar technologies. Quantum Surgical’s CEO, Jean-Luc Pagès, expressed his enthusiasm for the collaboration with King’s College Hospital. "We are thrilled to see our technology being adopted by such a respected institution. The Epione® platform is the result of years of dedicated research, and we believe it will make a substantial difference in the lives of cancer patients. Our partnership with King’s College Hospital will help drive further innovation and improve patient care across the UK and beyond." The implementation of the Epione® robotic platform is expected to have a positive impact on patient outcomes and the overall efficiency of cancer treatments at King’s College Hospital. As more healthcare providers evaluate the benefits of this technology, it could pave the way for widespread adoption, bringing advanced and precise treatment options to a larger number of patients. With the introduction of the Epione® system, King’s College Hospital NHS Foundation Trust continues to set a new standard for cancer care, combining the expertise of its medical professionals with the latest in robotic technology to offer patients the best possible treatment options.